CTAD 2025 1 - 4 December 2025

Effects of Semaglutide on Alzheimer’s Disease-Related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer’s Disease After 12 Weeks of Treatment

Authors :

Kristian Steen Frederiksen^1,2; Marie Aare Bentsen³; Dylan Matthew Belmont-Rausch³; Lisbeth Carstensen³; Brian Cutler⁴; Redwan Farooq⁴; Lea Hildebrandt³; Martí Jiménez-Mausbach³; Peter Johannsen³; Gabriel Martino³; Joseph Polex-Wolf³; Amaya Zaratiegui³; Giovanni B. Frisoni^5,6; Kathrine E. Attfield⁴; Lotte Bjerre Knudsen³

Affiliations

View Details Hide Details

Keywords

Neurodegenerative diseases

Congress oral presentation

GLP-1 RA

Semaglutide

PHASE 3 (RCT)

Search Science Hub

Are you a healthcare professional?

Effects of Semaglutide on Alzheimer’s Disease-Related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer’s Disease After 12 Weeks of Treatment